Recent Updates
Recently added Catalysts

insulin human

Phase 3

Diabetes | Small molecule | Metabolic |Novo Nordisk A/S|Last Updated: Dec 22, 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials1
Total Enrollment378

FDA Designations

No designations recorded

Clinical trial landscape

insulin human · 1 trial · 2 indications

Phase 3 1
NCT00071448Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric PopulationDiabetes
COMPLETED378 Analytics
PHASE3COMPLETED
Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population
DiabetesUnlock trial analytics

Study Endpoints

Primary Endpoints

HbA1c (glycosylated haemoglobin A1c)

Secondary Endpoints

FPG (fasting plasma glucose)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
insulin humanDRUG -
insulin lisproDRUG -
insulin aspartDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range6 Years to 18 Years
SexALL
Healthy VolunteersYes
Study Sites76

Inclusion Criteria: * Pediatric patients with Type 1 diabetes for at least one year * HbA1c less than 12% * Willing to administer at least 3 injections per day * Willing to perform self monitored blood glucose (SMBG) at least 4 times per day, includes subject and/or parent/guardian, as necessary

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Diabetes Complications 6 trials (matched to "Diabetes")